Roberto Maggio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9305624/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A 5-Year Study of Lithium and Valproic Acid Drug Monitoring in Patients with Bipolar Disorders in an Italian Clinical Center. Pharmaceuticals, 2022, 15, 105.	3.8	5
2	Interaction of the preferential D3 agonist (+)PHNO with dopamine D3-D2 receptor heterodimers and diverse classes of monoamine receptor: relevance for PET imaging. European Journal of Pharmacology, 2022, 925, 175016.	3.5	0
3	Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences. Pharmaceuticals, 2021, 14, 238.	3.8	80
4	Romidepsin (FK228) fails in counteracting the transformed phenotype of rhabdomyosarcoma cells but efficiently radiosensitizes, inÂvitro and inÀvivo, the alveolar phenotype subtype. International Journal of Radiation Biology, 2021, 97, 943-957.	1.8	13
5	β-Cells Different Vulnerability to the Parkinsonian Neurotoxins Rotenone, 1-Methyl-4-phenylpyridinium (MPP+) and 6-Hydroxydopamine (6-OHDA). Pharmaceuticals, 2021, 14, 767.	3.8	4
6	MS-275 (Entinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 Rhabdomyosarcoma Cells. International Journal of Molecular Sciences, 2021, 22, 10671.	4.1	14
7	Is Adult Hippocampal Neurogenesis Really Relevant for the Treatment of Psychiatric Disorders?. Current Neuropharmacology, 2021, 19, 1640-1660.	2.9	10
8	Integration and Spatial Organization of Signaling by G Protein-Coupled Receptor Homo- and Heterodimers. Biomolecules, 2021, 11, 1828.	4.0	5
9	Allosteric Modulators of G Protein-Coupled Dopamine and Serotonin Receptors: A New Class of Atypical Antipsychotics. Pharmaceuticals, 2020, 13, 388.	3.8	16
10	Clinically relevant radioresistant rhabdomyosarcoma cell lines: functional, molecular and immune-related characterization. Journal of Biomedical Science, 2020, 27, 90.	7.0	18
11	Antitumorigenic Effects of Inhibiting Ephrin Receptor Kinase Signaling by GLPG1790 against Colorectal Cancer Cell Lines <i>In Vitro</i> and <i>In Vivo</i> . Journal of Oncology, 2020, 2020, 1-16.	1.3	9
12	A New Threat to Dopamine Neurons: The Downside of Artificial Light. Neuroscience, 2020, 432, 216-228.	2.3	13
13	Neurotoxic and Neuroprotective Role of Exosomes in Parkinson's Disease. Current Pharmaceutical Design, 2020, 25, 4510-4522.	1.9	17
14	Pro-differentiating and radiosensitizing effects of inhibiting HDACs by PXD-101 (Belinostat) in in vitro and in vivo models of human rhabdomyosarcoma cell lines. Cancer Letters, 2019, 461, 90-101.	7.2	22
15	Parkinson's disease and light: The bright and the Dark sides. Brain Research Bulletin, 2019, 150, 290-296.	3.0	10
16	Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma. Journal of Cancer Research and Clinical Oncology, 2019, 145, 393-409.	2.5	25
17	Distinctive binding properties of the negative allosteric modulator, [3 H]SB269,652, at recombinant dopamine D 3 receptors. European Journal of Pharmacology, 2018, 819, 181-189.	3.5	5
18	Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences. , 2018,		140

2

ROBERTO MAGGIO

#	Article	IF	CITATIONS
19	Dopamine D2 Receptors Dimers: How can we Pharmacologically Target Them?. Current Neuropharmacology, 2018, 16, 222-230.	2.9	27
20	The First Negative Allosteric Modulator for Dopamine D ₂ and D ₃ Receptors, SB269652 May Lead to a New Generation of Antipsychotic Drugs. Molecular Pharmacology, 2017, 91, 586-594.	2.3	33
21	Fluorescent light induces neurodegeneration in the rodent nigrostriatal system but near infrared LED light does not. Brain Research, 2017, 1662, 87-101.	2.2	20
22	Historical Perspectives: From Monomers to Dimers and Beyond, an Exciting Journey in the World of G Protein-Coupled Receptors. , 2017, , 3-14.		2
23	Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells. Journal of Hematology and Oncology, 2017, 10, 161.	17.0	29
24	Dichlorodiphenyltrichloroethane (DDT) induced extracellular vesicle formation: a potential role in organochlorine increased risk of Parkinson's disease. Acta Neurobiologiae Experimentalis, 2017, 77, 113-117.	0.7	8
25	Dysbindinâ€1 modifies signaling and cellular localization of recombinant, human D ₃ and D ₂ receptors. Journal of Neurochemistry, 2016, 136, 1037-1051.	3.9	7
26	Revealing Gâ€proteinâ€coupled receptor oligomerization at the singleâ€molecule level through a nanoscopic lens: methods, dynamics and biological function. FEBS Journal, 2016, 283, 1197-1217.	4.7	61
27	Variants of G protein-coupled receptors: a reappraisal of their role in receptor regulation. Biochemical Society Transactions, 2016, 44, 589-594.	3.4	8
28	Novel dimensions of D3 receptor function: Focus on heterodimerisation, transactivation and allosteric modulation. European Neuropsychopharmacology, 2015, 25, 1470-1479.	0.7	34
29	The atypical antipsychotic clozapine selectively inhibits interleukin 8 (IL-8)-induced neutrophil chemotaxis. European Neuropsychopharmacology, 2015, 25, 413-424.	0.7	15
30	Eyes as Gateways for Environmental Light to the Substantia Nigra: Relevance in Parkinson's Disease. Scientific World Journal, The, 2014, 2014, 1-7.	2.1	6
31	Nitric oxide synthase inhibition reverts muscarinic receptor down-regulation induced by pilocarpine- and kainic acid-evoked seizures in rat fronto-parietal cortex. Epilepsy Research, 2014, 108, 11-19.	1.6	3
32	Increase in mortality rate in patients with dementia treated with atypical antipsychotics: a cohort study in outpatients in Central Italy. Rivista Di Psichiatria, 2014, 49, 34-40.	0.6	17
33	Experimental Strategies for Studying G Protein-Coupled Receptor Homo- and Heteromerization with Radioligand Binding and Signal Transduction Methods. Methods in Enzymology, 2013, 521, 295-310.	1.0	10
34	Semiotic Selection of Mutated or Misfolded Receptor Proteins. Biosemiotics, 2013, 6, 177-190.	1.4	3
35	Bright light exposure reduces TH-positive dopamine neurons: implications of light pollution in Parkinson's disease epidemiology. Scientific Reports, 2013, 3, 1395.	3.3	44
36	Differential induction of adenylyl cyclase supersensitivity by antiparkinson drugs acting as agonists at dopamine D1/D2/D3 receptors vs D2/D3 receptors only: Parallel observations from co-transfected human and native cerebral receptors. Neuropharmacology, 2011, 60, 439-445.	4.1	16

Roberto Maggio

#	Article	IF	CITATIONS
37	The insecticide 1,1,1-trichloro-2,2-bis(p-chlorophenyl) ethane (DDT) alters the membrane raft location of the TSH receptor stably expressed in Chinese hamster ovary cells. Toxicology and Applied Pharmacology, 2011, 253, 121-129.	2.8	9
38	Are Olfactory Receptors Really Olfactive?. Biosemiotics, 2011, 4, 331-347.	1.4	6
39	A quantitative analysis of antidepressant and antipsychotic prescriptions following an earthquake in Italy. Journal of Traumatic Stress, 2011, 24, 129-132.	1.8	30
40	Genetic Deletion of Trace Amine 1 Receptors Reveals Their Role in Auto-Inhibiting the Actions of Ecstasy (MDMA). Journal of Neuroscience, 2011, 31, 16928-16940.	3.6	80
41	Receptor Oligomerization as a Process Modulating Cellular Semiotics. Biosemiotics, 2010, 3, 157-176.	1.4	8
42	Receptor crosstalk: haloperidol treatment enhances A2A adenosine receptor functioning in a transfected cell model. Purinergic Signalling, 2010, 6, 373-381.	2.2	10
43	The Tetrahydroisoquinoline Derivative SB269,652 Is an Allosteric Antagonist at Dopamine D ₃ and D ₂ Receptors. Molecular Pharmacology, 2010, 78, 925-934.	2.3	57
44	Dopamine D2–D3 receptor heteromers: pharmacological properties and therapeutic significance. Current Opinion in Pharmacology, 2010, 10, 100-107.	3.5	72
45	Presence of a putative steroidal allosteric site on glycoprotein hormone receptors. European Journal of Pharmacology, 2009, 623, 155-159.	3.5	21
46	Heterodimerization of dopamine receptors: new insights into functional and therapeutic significance. Parkinsonism and Related Disorders, 2009, 15, S2-S7.	2.2	60
47	Partial agonist actions at dopamine D2L receptors are modified by co-transfection of D3 receptors: Potential role of heterodimer formation. Parkinsonism and Related Disorders, 2008, 14, S139-S144. S33138	2.2	5
48	A Preferential Dopamine D ₃ versus D ₂ Receptor Antagonist and Potential Antipsychotic Agent: I. Receptor-Binding Profile and Functional Actions at G-Protein-Coupled	2.5	61
49	Receptors. Journal of Pharmacology and Experimental Therapeutics, 2008, 324, 587-599. The Thyroid Disruptor 1,1,1-Trichloro-2,2-Bis(p-Chlorophenyl)-Ethane Appears to Be an Uncompetitive Inverse Agonist for the Thyrotropin Receptor. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 465-474.	2.5	34
50	Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D2Lreceptors are modified by co-transfection of D3receptors: potential role of heterodimer formation. Journal of Neurochemistry, 2007, 102, 1410-1424.	3.9	45
51	G protein-coupled receptor oligomerization provides the framework for signal discrimination. Journal of Neurochemistry, 2007, 103, 1741-1752.	3.9	42
52	The impact of Câ€proteinâ€coupled receptor heteroâ€oligomerization on function and pharmacology. FEBS Journal, 2005, 272, 2939-2946.	4.7	82
53	Paired Activation of Two Components within Muscarinic M3 Receptor Dimers Is Required for Recruitment of β-Arrestin-1 to the Plasma Membrane. Journal of Biological Chemistry, 2005, 280, 19768-19776.	3.4	42
54	The Paired Activation of the Two Components of the Muscarinic M3 Receptor Dimer Is Required for Induction of ERK1/2 Phosphorylation. Journal of Biological Chemistry, 2004, 279, 7476-7486.	3.4	38

ROBERTO MAGGIO

#	Article	IF	CITATIONS
55	Heterodimerization of G-Protein-Coupled Receptors Reveals an Unexpected Level of Pharmacological Diversity. Medicinal Chemistry Research, 2004, 13, 25-33.	2.4	2
56	Polyamines May Modulate Both G Protein-Coupled Receptors and G Proteins. Medicinal Chemistry Research, 2004, 13, 63-73.	2.4	1
57	Dextromethorphan prevents the diethyldithiocarbamate enhancement of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice. Brain Research, 2003, 973, 298-302.	2.2	12
58	Functional rescue of the inactive splice variant of the dopamine D3 receptor D3nf. Brain Research, 2003, 987, 244-247.	2.2	7
59	Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole. Journal of Neurochemistry, 2003, 87, 631-641.	3.9	69
60	An Unusual Form of the Association Binding Kinetics ofN-[3H]Methylscopolamine to the Split Muscarinic M2trunk/M2tail Receptor. Journal of Pharmacology and Experimental Therapeutics, 2003, 305, 786-795.	2.5	6
61	Deoxamuscaroneoxime derivatives as useful muscarinic agonists to explore the muscarinic subsite. Life Sciences, 2002, 70, 1427-1446.	4.3	3
62	Sodium Nitroprusside Induces Internalization of Muscarinic Receptors Stably Expressed in Chinese Hamster Ovary Cell Lines. Journal of Neurochemistry, 2002, 65, 943-946.	3.9	12
63	Stimulatory role of dopamine on fibroblast growth factorâ€⊋ expression in rat striatum. Journal of Neurochemistry, 2001, 76, 990-997.	3.9	48
64	Apomorphine, dopamine and phenylethylamine reduce the proportion of phosphorylated insulin receptor substrate 1. European Journal of Pharmacology, 2001, 433, 47-54.	3.5	11
65	D2/D3 Dopamine Receptor Heterodimers Exhibit Unique Functional Properties. Journal of Biological Chemistry, 2001, 276, 30308-30314.	3.4	196
66	Reconstitution of functional dopamine D2s receptor by co-expression of amino- and carboxyl-terminal receptor fragments. European Journal of Pharmacology, 2000, 397, 291-296.	3.5	24
67	Dopamine agonists and analogues have an antiproliferative effect on CHO-K1 cells. Neurotoxicity Research, 1999, 1, 285-297.	2.7	7
68	Antagonist binding profile of the split chimeric muscarinic m2-trunc/m3-tail receptor. European Journal of Pharmacology, 1998, 355, 267-274.	3.5	9
69	Nicotine Prevents Experimental Parkinsonism in Rodents and Induces Striatal Increase of Neurotrophic Factors. Journal of Neurochemistry, 1998, 71, 2439-2446.	3.9	187
70	l-Deprenyl fails to protect mesencephalic dopamine neurons and PC12 cells from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion. Brain Research, 1996, 741, 68-74.	2.2	16
71	Functional Role of the Third Cytoplasmic Loop in Muscarinic Receptor Dimerization. Journal of Biological Chemistry, 1996, 271, 31055-31060.	3.4	90
72	Stereoselective inhibition of muscarinic receptor subtypes by the eight stereoisomers related to rociverine. European Journal of Pharmacology, 1995, 290, 125-132.	2.6	16

Roberto Maggio

#	Article	IF	CITATIONS
73	Role of excitatory amino-acids in diethyldithiocarbamate-induced cell death in mesencephalic cultures. Brain Research, 1995, 674, 127-132.	2.2	8
74	Inhibition of nitric oxide synthase dramatically potentiates seizures induced by kainic acid and pilocarpine in rats. Brain Research, 1995, 679, 184-187.	2.2	66
75	Binding profile of the selective muscarinic receptor antagonist tripitramine. European Journal of Pharmacology, 1994, 268, 459-462.	2.6	46
76	(+)MK-801 prevents the DDC-induced enhancement of MPTP toxicity in mice. Brain Research, 1994, 668, 194-203.	2.2	30
77	Motor expression of kainic acid seizures is attenuated by dopamine depletion in mice. Brain Research, 1994, 657, 269-274.	2.2	6
78	Reconstitution of functional muscarinic receptors by co-expression of amino- and carboxyl-terminal receptor fragments. FEBS Letters, 1993, 319, 195-200.	2.8	115
79	Blockade of GABA receptors in superior colliculus protects against focally evoked limbic motor seizures. Brain Research, 1993, 603, 279-283.	2.2	47
80	Expression of c-fos mRNA Following Seizures Evoked from an Epileptogenic Site in the Deep Prepiriform Cortex: Regional Distribution in Brain as Shown by in Situ Hybridization. Experimental Neurology, 1993, 119, 11-19.	4.1	42
81	Temporal and Spatial Patterns of Expression of c-fos, zif/268, c-jun and jun-B mRNAs in Rat Brain Following Seizures Evoked Focally from the Deep Prepiriform Cortex. Experimental Neurology, 1993, 119, 20-31.	4.1	77
82	Lack of proconvulsant action of GABA depletion in substantia nigra in several seizure models. Brain Research, 1991, 547, 1-6.	2.2	42
83	Selective stimulation of kainate but not quisqualate or NMDA receptors in substantia nigra evokes limbic motor seizures. Brain Research, 1990, 528, 223-230.	2.2	24
84	Seizures evoked from area tempestas are subject to control by GABA and glutamate receptors in substantia nigra. Experimental Neurology, 1989, 105, 184-188.	4.1	69
85	High affinity binding sites for 1-methyl-4-phenyl-pyridinium ion (MPP+) are present in mouse brain. European Journal of Pharmacology, 1986, 129, 87-92.	3.5	11